{"id":"https://openalex.org/W2007252822","doi":"https://doi.org/10.1002/art.20221","title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","display_name":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","publication_year":2004,"publication_date":"2004-05-01","ids":{"openalex":"https://openalex.org/W2007252822","doi":"https://doi.org/10.1002/art.20221","mag":"2007252822","pmid":"https://pubmed.ncbi.nlm.nih.gov/15146410"},"language":"en","primary_location":{"id":"doi:10.1002/art.20221","doi":"https://doi.org/10.1002/art.20221","is_oa":false,"landing_page_url":"https://doi.org/10.1002/art.20221","pdf_url":null,"source":{"id":"https://openalex.org/S132787887","display_name":"Arthritis & Rheumatism","issn_l":"0004-3591","issn":["0004-3591","1529-0131"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2007252822"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100607192","display_name":"Mark C. Genovese","orcid":"https://orcid.org/0000-0001-5294-4503","observed_orcids":["https://orcid.org/0000-0001-5294-4503"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark C. Genovese","raw_affiliation_strings":["Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. genovese@stanford.edu","Stanford University, Palo Alto, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. genovese@stanford.edu","institution_ids":["https://openalex.org/I97018004"]},{"raw_affiliation_string":"Stanford University, Palo Alto, California","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057538503","display_name":"Stanley B. Cohen","orcid":"https://orcid.org/0000-0002-9226-979X","observed_orcids":["https://orcid.org/0000-0002-9226-979X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stanley Cohen","raw_affiliation_strings":["St. Paul Medical Center, Dallas, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. Paul Medical Center, Dallas, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066780563","display_name":"Larry W. Moreland","orcid":"https://orcid.org/0000-0003-4483-0359","observed_orcids":["https://orcid.org/0000-0003-4483-0359"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Moreland","raw_affiliation_strings":["University of Alabama at, Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at, Birmingham","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081395405","display_name":"D. Lium","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah Lium","raw_affiliation_strings":["Amgen  Thousand Oaks California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen  Thousand Oaks California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027830729","display_name":"Sean Robbins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Robbins","raw_affiliation_strings":["Amgen  Thousand Oaks California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen  Thousand Oaks California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108572423","display_name":"Richard Newmark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Newmark","raw_affiliation_strings":["Amgen  Thousand Oaks California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen  Thousand Oaks California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026972469","display_name":"Pirow J. Bekker","orcid":"https://orcid.org/0000-0003-0219-7188","observed_orcids":["https://orcid.org/0000-0003-0219-7188"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pirow Bekker","raw_affiliation_strings":["Amgen, Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":null,"display_name":"for the 20000223 Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"for the 20000223 Study Group","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":18.6539,"has_fulltext":false,"cited_by_count":538,"citation_normalized_percentile":{"value":0.99653465,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"50","issue":"5","first_page":"1412","last_page":"1419"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9940000176429749},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.9850000143051147},{"id":"https://openalex.org/keywords/anakinra","display_name":"anakinra","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9700000286102295},{"id":"https://openalex.org/keywords/anti-tnf-therapy","display_name":"anti-TNF therapy","score":0.7160000205039978},{"id":"https://openalex.org/keywords/anti-interleukin-1-therapy","display_name":"anti-interleukin-1 therapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/methotrexate-refractory-disease","display_name":"methotrexate-refractory disease","score":0.8899999856948853},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5149999856948853},{"id":"https://openalex.org/keywords/severe-infection","display_name":"serious infections","score":0.8960000276565552},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.7720000147819519},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8840000033378601},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9129999876022339},{"id":"https://openalex.org/keywords/acr-response","display_name":"ACR response","score":0.4490000009536743}],"concepts":[{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.9557417631149292},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9281888008117676},{"id":"https://openalex.org/C2781228260","wikidata":"https://www.wikidata.org/wiki/Q415411","display_name":"Anakinra","level":3,"score":0.8963626027107239},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.7318623661994934},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.6366880536079407},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.553334653377533},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5512418150901794},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.46153151988983154},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.43759605288505554},{"id":"https://openalex.org/C198451711","wikidata":"https://www.wikidata.org/wiki/Q327657","display_name":"Rheumatology","level":2,"score":0.43609803915023804},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3457016944885254},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.09303319454193115}],"mesh":[{"descriptor_ui":"D000068800","descriptor_name":"Etanercept","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012795","descriptor_name":"Sialoglycoproteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D012795","descriptor_name":"Sialoglycoproteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012795","descriptor_name":"Sialoglycoproteins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018124","descriptor_name":"Receptors, Tumor Necrosis Factor","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D053590","descriptor_name":"Interleukin 1 Receptor Antagonist Protein","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/art.20221","doi":"https://doi.org/10.1002/art.20221","is_oa":false,"landing_page_url":"https://doi.org/10.1002/art.20221","pdf_url":null,"source":{"id":"https://openalex.org/S132787887","display_name":"Arthritis & Rheumatism","issn_l":"0004-3591","issn":["0004-3591","1529-0131"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatism","raw_type":"journal-article"},{"id":"pmid:15146410","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15146410","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis and rheumatism","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W614531583","https://openalex.org/W1973672167","https://openalex.org/W1978103379","https://openalex.org/W1985004174","https://openalex.org/W2000905503","https://openalex.org/W2028290269","https://openalex.org/W2032140498","https://openalex.org/W2033299724","https://openalex.org/W2065419533","https://openalex.org/W2091732273","https://openalex.org/W2098015378","https://openalex.org/W2125438927","https://openalex.org/W2133692536","https://openalex.org/W2152348310","https://openalex.org/W2159106700","https://openalex.org/W2314052274","https://openalex.org/W2319957449","https://openalex.org/W2340084730","https://openalex.org/W2620189731"],"related_works":["https://openalex.org/W2620189731","https://openalex.org/W2149456330","https://openalex.org/W2116843833","https://openalex.org/W2403272694","https://openalex.org/W2163339916","https://openalex.org/W2080506899","https://openalex.org/W2462013310","https://openalex.org/W2322859699","https://openalex.org/W142190074","https://openalex.org/W4297937755"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"the":[3,14,23,84,98,112,120,159,172,189,232,263],"potential":[4],"for":[5,73,210,214,262],"additive":[6],"or":[7,62,234],"synergistic":[8],"effects":[9],"of":[10,101,122,131,158,171,188,206,236,265],"combination":[11,215,224],"therapy":[12,41,145,227,241],"with":[13,44,97,146,164,175,186,192,223,242,255,267],"selective":[15],"anti-tumor":[16],"necrosis":[17],"factor":[18],"alpha":[19],"agent":[20,25],"etanercept":[21,46,53,64,147,155,177,193,211,243,256],"and":[22,111,125,134,219,244,250,258],"anti-interleukin-1":[24],"anakinra.":[26],"METHODS:":[27],"Two":[28],"hundred":[29],"forty-four":[30],"patients":[31,173,190,266],"in":[32,76,83],"whom":[33],"rheumatoid":[34],"arthritis":[35],"(RA)":[36],"was":[37,95,117,162,197,221],"active":[38],"despite":[39],"methotrexate":[40],"were":[42,140],"treated":[43,174,191],"subcutaneous":[45],"only":[47],"(25":[48,54,65],"mg":[49,55,66],"twice":[50,56],"weekly),":[51],"full-dosage":[52,176],"weekly)":[57,68],"plus":[58,69,148,178],"anakinra":[59,70,149,179,245],"(100":[60,71],"mg/day),":[61],"half-dosage":[63],"once":[67],"mg/day)":[72],"6":[74],"months":[75],"a":[77,107],"double-blind":[78],"study":[79],"at":[80],"41":[81],"centers":[82],"US.":[85],"Patients":[86],"had":[87,228],"never":[88],"previously":[89],"received":[90],"anticytokine":[91],"therapy.":[92,225],"Patient":[93],"response":[94],"measured":[96],"American":[99],"College":[100],"Rheumatology":[102],"(ACR)":[103],"core":[104],"set":[105],"criteria,":[106],"health-related":[108],"quality-of-life":[109],"questionnaire,":[110],"Disease":[113],"Activity":[114],"Score.":[115],"Safety":[116],"assessed":[118],"by":[119],"number":[121],"adverse":[123],"events":[124],"clinical":[126],"laboratory":[127],"values.":[128],"Plasma":[129],"concentrations":[130],"both":[132,138],"agents":[133,139],"antibody":[135],"formation":[136],"against":[137],"also":[141],"assessed.":[142],"RESULTS:":[143],"Combination":[144,226,240],"provided":[150],"no":[151,229,247],"treatment":[152,264],"benefit":[153,249],"over":[154],"alone,":[156,212],"regardless":[157],"regimen,":[160],"but":[161],"associated":[163],"an":[165,181,251],"increased":[166,222,252],"safety":[167],"risk.":[168],"Thirty-one":[169],"percent":[170],"achieved":[180],"ACR":[182],"50%":[183],"response,":[184],"compared":[185,254],"41%":[187],"only.":[194],"This":[195],"result":[196],"not":[198,260],"statistically":[199],"significant":[200],"(P":[201],"=":[202],"0.914).":[203],"The":[204],"incidence":[205],"serious":[207],"infections":[208],"(0%":[209],"3.7-7.4%":[213],"therapy),":[216],"injection-site":[217],"reactions,":[218],"neutropenia":[220],"effect":[230],"on":[231],"pharmacokinetics":[233],"immunogenicity":[235],"either":[237],"agent.":[238],"CONCLUSION:":[239],"provides":[246],"added":[248],"risk":[253],"alone":[257],"is":[259],"recommended":[261],"RA.":[268]},"counts_by_year":[{"year":2026,"cited_by_count":22},{"year":2025,"cited_by_count":16},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":23},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":19},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":22},{"year":2017,"cited_by_count":23},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":26},{"year":2014,"cited_by_count":26},{"year":2013,"cited_by_count":29},{"year":2012,"cited_by_count":23}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}